Immunovant (IMVT) Research & Development (2018 - 2026)
Immunovant's (IMVT) quarterly Research & Development came in at $142.3 million in Q1 2026, up 51.93% YoY from $93.7 million in Q1 2025, and up 43.83% on a QoQ basis from $98.9 million in Q4 2025.
Immunovant (IMVT) Research & Development (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Research & Development data on file, last reported at $142.3 million in Q1 2026.
- Quarterly Research & Development rose 51.93% year-over-year to $142.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $456.7 million (up 26.53% YoY) and the FY2026 annual result came in at $456.7 million, up 26.53% from the prior year.
- Research & Development improved to $142.3 million in Q1 2026, from $98.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $142.3 million in Q1 2026 to a low of $28.4 million in Q2 2022.
- A 5-year average of $71.9 million and a median of $66.1 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development soared 102.82% — and 2025, when it increased 4.66%.
- Tracing IMVT's Research & Development over 5 years: stood at $42.3 million in 2022, then increased by 14.4% to $48.3 million in 2023, then soared by 95.54% to $94.5 million in 2024, then gained by 4.66% to $98.9 million in 2025, then jumped by 43.83% to $142.3 million in 2026.
- The last three Research & Development figures came in at $142.3 million (Q1 2026), $98.9 million (Q4 2025), and $114.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 142.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 142.63 Mn |
| Mar 31, 2026 | 142.29 Mn |
| Dec 31, 2025 | 98.92 Mn |
| Sep 30, 2025 | 114.25 Mn |
| Jun 30, 2025 | 101.20 Mn |
| Mar 31, 2025 | 93.65 Mn |
| Dec 31, 2024 | 94.52 Mn |
| Sep 30, 2024 | 97.27 Mn |
| Jun 30, 2024 | 75.47 Mn |
| Mar 31, 2024 | 66.06 Mn |
| Dec 31, 2023 | 48.34 Mn |
| Sep 30, 2023 | 47.96 Mn |
| Jun 30, 2023 | 50.58 Mn |
| Mar 31, 2023 | 51.84 Mn |
| Dec 31, 2022 | 42.25 Mn |
| Sep 30, 2022 | 37.74 Mn |
| Jun 30, 2022 | 28.43 Mn |
| Mar 31, 2022 | 31.99 Mn |
| Dec 31, 2021 | 29.76 Mn |
| Sep 30, 2021 | 21.36 Mn |